top of page

Fighting drug-resistant TB was costly. Here's how that's changed

resisttb

Phumeza Tisile was treated for MDR-TB in 2010 and suffered severe side effects from the drug, kanamycin. Her experiences drove her to join the global bedaquiline advocacy campaign. After years of work from the campaign, including legal opposition to J&J’s patents, nearly universal access to bedaquiline was achieved in 2023, preventing J&J from extending its monopoly and enabling generic production. Tisile describes her work on the campaign and the challenges they faced along the way to make bedaquiline widely accessible. Read more here.

25 views0 comments

Recent Posts

See All

Armand Van Deun Scholarship Initiative

The Institute of Tropical Medicine has announced two initiatives to honor the legacy of Armand Van Deun: a new meeting room in his name...

Commentaires


bottom of page